Skip to main content
Tech.euFundingExplorerBeta

Nouscom

Develops tumor specific oncolytic viruses and patient specific cancer vaccines

Nouscom has raised €174M across 3 funding rounds from 16 investors, most recently a Series B round in Oct 2026. Based in Basel, Switzerland; active in Healthtech. Data as of 28 Oct 2026.

Total raised
€174M
€174,267,261
Funding rounds
3
Investors
16
distinct backers
Active since
2016-05
latest 2026-10

Funding by year

EUR raised per year · 2026 YTD
Nouscom — funding by year — interactive chart.
Data table
Nouscom — funding by year
2016€12M
2017€42M
2026€120M

Signals

High confidence
Raise-next likelihood18
base rate 48% for Series B
  • ▼ Raised very recently
  • ▲ Up-round momentum
  • ▼ Low backer re-investment
Exit likelihood24
base rate 11% (2+ rounds)
  • ▲ €100M+ raised
  • ▲ 10y since founding (typical exit age)
  • ▲ Recently backed by strong-exit-track investors

Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.

Funding rounds

3 rounds

Similar companies

same sector or country

Global coverage: FundingData